Our Collaborators

In June 2019, SpringWorks entered into a clinical collaboration with GlaxoSmithKline to conduct a Phase 1b study to evaluate the safety, tolerability and preliminary efficacy of nirogacestat in combination with GlaxoSmithKline’s BCMA antibody-drug conjugate, BLENREP (belantamab mafodotin), in patients with relapsed or refractory multiple myeloma. Read more

In January 2020, SpringWorks entered into a clinical collaboration with Allogene Therapeutics to conduct a Phase 1 study to evaluate the safety, tolerability and preliminary efficacy of nirogacestat in combination with Allogene’s investigational BCMA AlloCAR TTM therapy in patients with relapsed or refractory multiple myeloma. Read more

In September 2020, SpringWorks entered into a clinical collaboration with Janssen Biotech, Inc. to conduct a Phase 1 study to evaluate the safety, tolerability and preliminary efficacy of nirogacestat in combination with Janssen’s investigational BCMA CD3 bispecific antibody, teclistamab, in patients with relapsed or refractory multiple myeloma. Read more

In September 2020, SpringWorks entered into a clinical collaboration with Precision BioSciences to conduct a Phase 1 study to evaluate the safety, tolerability and preliminary efficacy of nirogacestat, in combination with Precision BioSciences’ investigational BCMA allogeneic CAR T cell therapy, PBCAR269A, in patients with relapsed or refractory multiple myeloma. Read more

In September 2020, SpringWorks entered into a sponsored research agreement with the Fred Hutchinson Cancer Research Center to further evaluate nirogacestat’s ability to modulate BCMA and potentiate BCMA-targeted therapies in a variety of preclinical and patient-derived multiple myeloma models developed by researchers at Fred Hutch. Read more

In October 2020, SpringWorks entered into a clinical collaboration with Pfizer to conduct a Phase 1b/2 study to evaluate the safety, tolerability and preliminary efficacy of nirogacestat in combination with Pfizer’s investigational BCMA CD3 bispecific antibody, PF‐06863135, in patients with relapsed or refractory multiple myeloma. Read more

In August 2018, SpringWorks entered into a clinical collaboration with BeiGene to evaluate the safety, tolerability, and preliminary efficacy of BeiGene’s investigational RAF-dimer inhibitor, lifirafenib (BGB-283), in combination with SpringWorks Therapeutics’ investigational MEK inhibitor, mirdametinib, in a range of genetically-defined solid tumors. Read more

In June 2019, SpringWorks and BeiGene announced the formation of MapKure, a clinical-stage company developing BGB-3245, an investigational, oral, selective small molecule inhibitor of monomer and dimer forms of activating BRAF mutations, including V600 BRAF mutations, non-V600 BRAF mutations and RAF fusions. Read more

In September 2020, SpringWorks entered into a collaboration with the Children’s Oncology Group to conduct a Phase 2 study to evaluate the safety, tolerability and preliminary efficacy of nirogacestat in children and adolescents with progressive, surgically unresectable desmoid tumors. Read more